<?xml version="1.0" encoding="UTF-8"?>
<results title="tropicalVirus">
 <result pre="VirusesVirusesvirusesViruses1999-4915MDPI pmcid: 6893414 doi: 10.3390/v11111064viruses-11-01064 : Article Erythromycin Estolate Inhibits" exact="Zika" post="Virus Infection by Blocking Viral Entry as a Viral"/>
 <result pre="the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract Recently," exact="Zika" post="virus (ZIKV) has attracted much attention in consideration of"/>
 <result pre="prophylactic vaccines or therapeutic drugs approved for clinical treatments of" exact="ZIKV" post="infection. To determine the potential anti-ZIKV inhibitors, we screened"/>
 <result pre="one of the macrolide antibiotics, was found to effectively inhibit" exact="ZIKV" post="infection in different cell types and significantly protect A129"/>
 <result pre="and mortality. Through further investigation, Ery-Est was verified to inhibit" exact="ZIKV" post="entry by disrupting the integrity of the viral membrane"/>
 <result pre="of the viral membrane which resulted in the loss of" exact="ZIKV" post="infectivity. Furthermore, Ery-Est also showed inhibitory activity against dengue"/>
 <result pre="Thus, Ery-Est may be a promising drug for patients with" exact="ZIKV" post="infection, particularly pregnant women. erythromycin estolate ZIKV viral entry"/>
 <result pre="for patients with ZIKV infection, particularly pregnant women. erythromycin estolate" exact="ZIKV" post="viral entry inhibitor inactivator 1. Introduction Zika virus (ZIKV),"/>
 <result pre="women. erythromycin estolate ZIKV viral entry inhibitor inactivator 1. Introduction" exact="Zika" post="virus (ZIKV), a mosquito-borne enveloped RNA virus, is a"/>
 <result pre="viruses, such as dengue virus (DENV), yellow fever virus (YFV)," exact="West Nile" post="virus, and Japanese encephalitis virus, which have resulted in"/>
 <result pre="resulted in epidemics and threatened public health around the world." exact="ZIKV" post="was initially isolated from a sentinel rhesus monkey in"/>
 <result pre="ZIKV was initially isolated from a sentinel rhesus monkey in" exact="Zika" post="forest, Uganda in 1947 [1,2], and had been perceived"/>
 <result pre="conjunctivitis. However, since 2007, the threat to public health from" exact="ZIKV" post="has steadily increased due to outbreaks in varying places,"/>
 <result pre="such as Yap Island, French Polynesia, and Micronesia [3,4]. Thus," exact="ZIKV" post="has been recognized as an emerging arbovirus and received"/>
 <result pre="arbovirus and received attention globally. More recently, unexpected outbreaks of" exact="ZIKV" post="infection have occurred in Brazil and rapidly spread from"/>
 <result pre="millions of residents [5]. Meanwhile, the neurological disorders caused by" exact="ZIKV" post="have been declared a global public health emergency by"/>
 <result pre="public health emergency by the World Health Organization (WHO) [6]." exact="ZIKV" post="was found to be associated with Guillain–Barré syndrome in"/>
 <result pre="abnormality, and reproductive system injury, have been discovered in recent" exact="ZIKV" post="outbreaks [7,8,9,10]. Microcephaly, the most worrying abnormality caused by"/>
 <result pre="life of affected children [11]. As the increasing cases of" exact="ZIKV" post="sexual transmission and multiple harmful outcomes to fetuses have"/>
 <result pre="conceive are now regarded as at especially high risk for" exact="ZIKV" post="infection, and thus the need for effective treatments has"/>
 <result pre="With the increasing recognition of the epidemiology and pathogenicity of" exact="ZIKV" post="infection, it is urgent to develop potent therapies. Currently,"/>
 <result pre="there are no vaccines or therapeutic drugs approved to treat" exact="ZIKV" post="infection, although great progress has been achieved. Many potent"/>
 <result pre="patients. Many already-approved drugs have been discovered to significantly inhibit" exact="ZIKV" post="infection, but few can be safely used by pregnant"/>
 <result pre="the safety profile for pregnant women in the development of" exact="ZIKV" post="inhibitors must be considered a priority. To determine the"/>
 <result pre="be considered a priority. To determine the ready-to-use inhibitors for" exact="ZIKV" post="infection, we screened a drug library consisting of FDA-approved"/>
 <result pre="be safely used by pregnant women, was found to inhibit" exact="ZIKV" post="infection efficiently. Ery-Est, one of the macrolide antibiotics, is"/>
 <result pre="and ivermectin and azithromycin (Azi) were identified to effectively inhibit" exact="ZIKV" post="infection [17,18,19,20,21,22,23]. To the best of our knowledge, this"/>
 <result pre="containing 10% FBS at 28 °C with 5% CO2. Three" exact="ZIKV" post="strains, SZ01 (GenBank: KU866423), FLR (GenBank: KU820897.5), and MR766"/>
 <result pre="monkey in Uganda in 1947 [1], were obtained from ATCC." exact="YFV" post="strain 17D was obtained from Beijing Tiantan Biological products,"/>
 <result pre="Tiantan Biological products, Ltd. and prepared as previously described [26]." exact="DENV" post="II strain New Guinea C was kindly provided by"/>
 <result pre="by Zhigang Song at Shanghai Public Health Clinical Center. The" exact="ZIKV" post="strains SZ01 (passage 6–8), MR766 (passage 4–6) and FLR"/>
 <result pre="SZ01 (passage 6–8), MR766 (passage 4–6) and FLR (passage 4–6)," exact="DENV" post="II strain New Guinea C (passage 5–7), and YFV"/>
 <result pre="4–6), DENV II strain New Guinea C (passage 5–7), and" exact="YFV" post="strain 17D (passage 5–7) were used in the experiments."/>
 <result pre="17D (passage 5–7) were used in the experiments. Besides the" exact="ZIKV" post="strain SZ01 prepared in Vero cells (V-ZIKV), all flaviviruses"/>
 <result pre="for Antiviral Activity For the drug screen, equal volume of" exact="ZIKV" post="strain SZ01 (100 PFU/mL) and compounds diluted in serum-free"/>
 <result pre="h. BHK21 cells (2 × 104) were infected with compounds-treated" exact="ZIKV" post="at 37 °C for 12 h, followed by replacing"/>
 <result pre="to the instruction manual. To evaluate the antiviral efficacy against" exact="ZIKV" post="(SZ01, FLR, and MR766) and DENV II New Guinea"/>
 <result pre="the antiviral efficacy against ZIKV (SZ01, FLR, and MR766) and" exact="DENV" post="II New Guinea C and YFV 17D, Ery-Est and"/>
 <result pre="FLR, and MR766) and DENV II New Guinea C and" exact="YFV" post="17D, Ery-Est and Ery were serially diluted in serum-free"/>
 <result pre="NC, USA). To test the inhibitory activity of Ery-Est against" exact="ZIKV" post="in neuronal cells, U-251 MG cells were used. Briefly,"/>
 <result pre="normalized to untreated infected cells. The inhibition of Ery-Est against" exact="ZIKV" post="in multiple rounds of infection was performed as previously"/>
 <result pre="× 105) were infected by 2 × 103 PFU of" exact="ZIKV" post="treated with Ery-Est (20 µM), Ery (20 µM), and"/>
 <result pre="supernatant was collected at different timepoints after infection, and the" exact="ZIKV" post="titers of collected supernatants were respectively detected by the"/>
 <result pre="was respectively collected at 48 h post infection, and the" exact="ZIKV" post="titers of collected supernatants were detected by the plaque"/>
 <result pre="Staining Assay To confirm the inhibitory activity of Ery-Est on" exact="ZIKV" post="infection, BHK21 and Vero cells were seeded onto coverslips"/>
 <result pre="24 h. The mixture of 2 × 103 PFU of" exact="ZIKV" post="and the equal volume of serially diluted Ery-Est (20,"/>
 <result pre="visualization. For the entry experiment, BHK21 cells were infected with" exact="ZIKV" post="in the presence of Ery-Est at 37 °C for"/>
 <result pre="and drugs. For the attachment assay, cells were infected with" exact="ZIKV" post="in the presence of Ery-Est at 4 °C for"/>
 <result pre="For the fusion assay, BHK21 cells were firstly infected with" exact="ZIKV" post="at 4 °C for 1 h to allow viral"/>
 <result pre="In the post-entry assay, after BHK21 cells were infected with" exact="ZIKV" post="at 37 °C for 1 h to allow viral"/>
 <result pre="and RT-qPCR To detect the genomic RNA released from the" exact="ZIKV" post="particles, the RNase digestion assay and RT-qPCR were developed"/>
 <result pre="previously described [27,35]. Briefly, Ery-Est and Ery were incubated with" exact="ZIKV" post="(1 × 103 PFU) at 37 °C for 2"/>
 <result pre="°C for 2 h. Then, the released RNA from treated" exact="ZIKV" post="was digested by micrococcal nuclease (New England BioLabs, Ipswich,"/>
 <result pre="as follows: F1 (5′-TGGAGGCTGAGATGGATGG-3′)/R1 (5′-GAACGCTGCGGTACACAAGGA-3′). 2.10. Sucrose Density Gradient Assay" exact="ZIKV" post="(1 × 106 PFU) with 100 µM Ery-Est, Ery,"/>
 <result pre="37 °C for 2 h. Then, the treated or untreated" exact="ZIKV" post="was gently loaded onto the top of the sucrose"/>
 <result pre="assigned into six groups and three groups were infected with" exact="ZIKV" post="strain SZ01 intraperitoneally (i.p.) at a dose of 1"/>
 <result pre="of 1 × 105 PFU/ mouse. At 1 h post" exact="ZIKV" post="challenge, infected mice were i.p. administrated with Ery-Est and"/>
 <result pre="tremors; and 5, moribund or death. Mice administrated with heat-inactivated" exact="ZIKV" post="(iZIKV) or only administrated with Ery-Est and Ery at"/>
 <result pre="four groups (n = 5). One group infected with heat-inactivated" exact="ZIKV" post="(iZIKV) was used as mock controls, and other three"/>
 <result pre="mock controls, and other three groups were i.p. infected with" exact="ZIKV" post="strain SZ01 at a dose of 2 × 105"/>
 <result pre="refers to the sample size. 3. Results 3.1. Ery-Est Inhibited" exact="ZIKV" post="Infection in Different Cell Types To determine the inhibitory"/>
 <result pre="Ery-Est and Ery of serially diluted concentrations were incubated with" exact="ZIKV" post="strain SZ01 at 37 °C for 1 h, and"/>
 <result pre="to BHK21 cells, which were reported to be susceptible to" exact="ZIKV" post="and develop obvious cytopathic effects (CPE) after infection [38],"/>
 <result pre="crystal violet dyeing. As shown in Figure 1B, numbers of" exact="ZIKV" post="plaques were reduced more as the concentration of Ery-Est"/>
 <result pre="the assay were generally unchanged. This suggests that Ery-Est inhibits" exact="ZIKV" post="infection in a dose-dependent manner. The 50% inhibitory concentration"/>
 <result pre="manner. The 50% inhibitory concentration (IC50) value of Ery-Est against" exact="ZIKV" post="was 3.22 ± 0.28 µM in the plaque assay"/>
 <result pre="(Figure 1C). To test the inhibitory activity of Ery-Est against" exact="ZIKV" post="in neuronal cells whose damage caused by ZIKV was"/>
 <result pre="Ery-Est against ZIKV in neuronal cells whose damage caused by" exact="ZIKV" post="was especially serious, which would reduce fetal brain growth,"/>
 <result pre="reduce fetal brain growth, U-251 MG cells were infected by" exact="ZIKV" post="with serially diluted Ery-Est and Ery treatments. It was"/>
 <result pre="with the data from the plaque assay. The expression of" exact="ZIKV" post="E protein was almost completely blocked by Ery-Est at"/>
 <result pre="in BHK21 and Vero cells (Figure 1E). Furthermore, CPE of" exact="ZIKV" post="in BHK21 and Vero cells would make cells progress"/>
 <result pre="viabilities, thus, could be detected by CCK8, which could evaluate" exact="ZIKV" post="infection indirectly. As a result, Ery-Est was testified to"/>
 <result pre="infection indirectly. As a result, Ery-Est was testified to inhibit" exact="ZIKV" post="strain SZ01 infection with IC50 values of 3.55 ±"/>
 <result pre="S1A,B). Taken together, these data indicate that Ery-Est notably inhibits" exact="ZIKV" post="infection in different cell types, including neuronal cells. In"/>
 <result pre="of Ery-Est against viral growth, Ery-Est was tested to inhibit" exact="ZIKV" post="infection in a multistep growth curve. It was demonstrated"/>
 <result pre="multistep growth curve. It was demonstrated that Ery-Est greatly decreased" exact="ZIKV" post="titers (supplementary Figure S2A) in multiple rounds of infection,"/>
 <result pre="that Ery-Est has a strong and lasting inhibitory effect on" exact="ZIKV" post="infection. Besides, it was also shown that Ery-Est could"/>
 <result pre="was also shown that Ery-Est could exhibit inhibitory activity against" exact="ZIKV" post="infection even with relatively higher viral doses (Figure S2B),"/>
 <result pre="against relatively higher dose infection of ZIKV. 3.2. Ery-Est Inhibited" exact="ZIKV" post="Strains FLR and MR766, DENV II, and YFV 17D"/>
 <result pre="of ZIKV. 3.2. Ery-Est Inhibited ZIKV Strains FLR and MR766," exact="DENV" post="II, and YFV 17D Infections As Ery-Est was demonstrated"/>
 <result pre="Ery-Est Inhibited ZIKV Strains FLR and MR766, DENV II, and" exact="YFV" post="17D Infections As Ery-Est was demonstrated to potently inhibit"/>
 <result pre="YFV 17D Infections As Ery-Est was demonstrated to potently inhibit" exact="ZIKV" post="strain SZ01, we then evaluated its inhibitory activity against"/>
 <result pre="strain SZ01, we then evaluated its inhibitory activity against other" exact="ZIKV" post="strains through plaque assay. As shown in Figure 2A,B,"/>
 <result pre="shown in Figure 2A,B, Ery-Est significantly inhibited the infections of" exact="ZIKV" post="strains FLR and MR766 with IC50 values of 7.65"/>
 <result pre="and 7.15 ± 0.96 µM respectively. Similar to strain SZ01," exact="ZIKV" post="strains MR766 and FLR were approximately half inhibited by"/>
 <result pre="inhibited by micromole Ery-Est, suggesting that Ery-Est could broadly inhibit" exact="ZIKV" post="strains that were isolated from rhesus monkeys or patients"/>
 <result pre="Ery-Est was able to inhibit other mosquito-borne flaviviruses, such as" exact="DENV" post="and YFV. It was demonstrated that Ery-Est potently inhibited"/>
 <result pre="YFV. It was demonstrated that Ery-Est potently inhibited infections of" exact="DENV" post="II and YFV 17D with IC50 values of about"/>
 <result pre="demonstrated that Ery-Est potently inhibited infections of DENV II and" exact="YFV" post="17D with IC50 values of about 1.22 ± 0.63"/>
 <result pre="2E,F). To rule out the possibility that Ery-Est only inhibits" exact="ZIKV" post="prepared in mosquito cells, we further tested whether Ery-Est"/>
 <result pre="further tested whether Ery-Est could effectively inhibit the infection of" exact="ZIKV" post="(V-ZIKV) produced in one kind of mammalian cells, Vero"/>
 <result pre="0.11 µM, which was similar to the inhibitory activity against" exact="ZIKV" post="propagated in mosquito cells. Meanwhile, both Ery-Est and Ery"/>
 <result pre="inhibit flavivirus infections with a broad spectrum. 3.3. Ery-Est Inhibited" exact="ZIKV" post="Infection in the Early Stage To determine which step"/>
 <result pre="time-of-addition experiment with different time points for Ery-Est addition post" exact="ZIKV" post="infection. At 12 h post infection, the supernatant was"/>
 <result pre="virus infection from 8 h post infection. Generally, Ery-Est inhibited" exact="ZIKV" post="infection mainly in the early 2 h stage post"/>
 <result pre="early 2 h stage post infection, indicating that Ery-Est inhibits" exact="ZIKV" post="infection in the early stage. Next, to confirm the"/>
 <result pre="exhibited obvious inhibitory effects on viral entry, but barely inhibited" exact="ZIKV" post="infection in the viral post-entry stage. The result was"/>
 <result pre="of different macrolide antibiotics may vary widely. 3.4. Ery-Est Inactivated" exact="ZIKV" post="Virons The above study of the inhibitory mechanism of"/>
 <result pre="the inhibitory mechanism of Ery-Est demonstrates that it mainly obstructs" exact="ZIKV" post="attachment, implying that Ery-Est may bind to viral particles"/>
 <result pre="its infectivity. We, thus, further investigated whether Ery-Est could inactivate" exact="ZIKV" post="directly. PEG-8000 was used to separate the treated ZIKV"/>
 <result pre="inactivate ZIKV directly. PEG-8000 was used to separate the treated" exact="ZIKV" post="virions from the free Ery-Est after the incubation of"/>
 <result pre="ZIKV virions from the free Ery-Est after the incubation of" exact="ZIKV" post="and Ery-Est or Ery as previously described [34]. The"/>
 <result pre="or Ery as previously described [34]. The infectivity of treated" exact="ZIKV" post="was then detected by plaque assay. Results showed that"/>
 <result pre="plaque assay. Results showed that Ery-Est decreased the infectivity of" exact="ZIKV" post="in a dose-dependent manner with 50% effective concentration of"/>
 <result pre="± 0.85 µM, while Ery showed no inactivated activity against" exact="ZIKV" post="(Figure 3C). Additionally, other mosquito-borne flaviviruses of DENV II"/>
 <result pre="activity against ZIKV (Figure 3C). Additionally, other mosquito-borne flaviviruses of" exact="DENV" post="II and YFV 17D were also used to verify"/>
 <result pre="(Figure 3C). Additionally, other mosquito-borne flaviviruses of DENV II and" exact="YFV" post="17D were also used to verify the inactivated effect"/>
 <result pre="of Ery-Est. As shown in Figure 3D,E, Ery-Est potently inactivated" exact="DENV" post="II and YFV 17D with 50% effective concentrations of"/>
 <result pre="shown in Figure 3D,E, Ery-Est potently inactivated DENV II and" exact="YFV" post="17D with 50% effective concentrations of 2.56 ± 0.11"/>
 <result pre="through directly inactivating viral particles. It was reported that some" exact="ZIKV" post="inhibitors, such as Z2 and human breast milk, could"/>
 <result pre="milk, could inactivate virus particles by destructing the integrity of" exact="ZIKV" post="[27,39]. Using similar approaches, we investigated whether Ery-Est inactivated"/>
 <result pre="ZIKV [27,39]. Using similar approaches, we investigated whether Ery-Est inactivated" exact="ZIKV" post="by inducing the release of genomic RNA from virions."/>
 <result pre="the RNase digestion assay, we found genomic RNA from untreated" exact="ZIKV" post="(0 µM Ery-Est) or treated by Ery were protected"/>
 <result pre="Ery were protected from RNase digestion, but the RNA of" exact="ZIKV" post="treated by Ery-Est was digested in a dose-dependence manner"/>
 <result pre="may cause the release of genomic RNA to inactivate the" exact="ZIKV" post="virions. Next, to further confirm this potential inactivated mechanism,"/>
 <result pre="ZIKV virions. Next, to further confirm this potential inactivated mechanism," exact="ZIKV" post="with media alone or respectively treated with Ery-Est and"/>
 <result pre="Western blot was used to measure the E protein of" exact="ZIKV" post="in each fraction of the above four treated groups,"/>
 <result pre="genomic RNA detection. Through the percent analysis of each fraction," exact="ZIKV" post="E protein and genomic RNA of Ery, DMSO, and"/>
 <result pre="ZIKV E protein and genomic RNA of Ery, DMSO, and" exact="ZIKV" post="(media alone) groups were consistently distributed in the fourth"/>
 <result pre="of viral integrity. These results indicate that Ery-Est may inhibit" exact="ZIKV" post="infection by destructing the viral integrity, resulting in the"/>
 <result pre="of genomic RNA. 3.5. Ery-Est Protected A129 Mice from Lethal" exact="ZIKV" post="Challenge As the results in vitro demonstrated that Ery-Est"/>
 <result pre="established transgenic (type I interferon receptor-deficient) A129 mouse model for" exact="ZIKV" post="lethal challenge [40]. Ery-Est and Ery were tested at"/>
 <result pre="an inhibitory role in the early stage, possibly by inactivating" exact="ZIKV" post="virions newly produced from the body and suppressing them"/>
 <result pre="more target cells. 3.6. Ery-Est Protected Against Vertical Transmission of" exact="ZIKV" post="in Pregnant C57BL/6 Mice To determine whether Ery-Est could"/>
 <result pre="by iZIKV (mock infected controls) or 2 × 105 PFU" exact="ZIKV" post="as described previously [27], followed by treatments of Ery-Est"/>
 <result pre="or vehicle treatments (Figure 5A). Meanwhile, the viral load of" exact="ZIKV" post="in placentas and fetal heads from pregnant mice with"/>
 <result pre="treatment. These results suggest that Ery-Est may directly inactivate some" exact="ZIKV" post="virions before they have penetrated to the placenta and"/>
 <result pre="placentas and fetuses, as well as blocking vertical transmission of" exact="ZIKV" post="in pregnant mice. 4. Discussion In consideration of worldwide"/>
 <result pre="mice. 4. Discussion In consideration of worldwide attention to recent" exact="ZIKV" post="outbreaks, many efforts have been made to explore potential"/>
 <result pre="against ZIKV. In our study, Ery-Est was demonstrated to inhibit" exact="ZIKV" post="infection in a dose-dependent manner in plaque assay (Figure"/>
 <result pre="could still suppress viral growth and exhibit inhibitory activity against" exact="ZIKV" post="infection even with relatively higher viral dose (Figure S2A,B),"/>
 <result pre="azithromycin and ivermectin, have been previously found to effectively inhibit" exact="ZIKV" post="infection. Moreover, azithromycin was reported to not only inhibit"/>
 <result pre="ZIKV infection. Moreover, azithromycin was reported to not only inhibit" exact="ZIKV" post="in vitro, but also to prevent ZIKV-induced lethality in"/>
 <result pre="research about why macrolide antibiotics exhibit different inhibitory mechanisms against" exact="ZIKV" post="is needed. As the effective macrolides with diverse characteristics"/>
 <result pre="baby with microcephaly [48,49,50,51]. Meanwhile, as the sexual transmission of" exact="ZIKV" post="was constantly reported [52,53], Ery-Est also showed great potential"/>
 <result pre="effects, which would not only block the sexual transmission of" exact="ZIKV" post="but would be conducive to the healthy vaginal environment."/>
 <result pre="thus, increases clinical options of the treatment and prevention for" exact="ZIKV" post="infection. Moreover, Ery-Est was demonstrated to protect against vertical"/>
 <result pre="Moreover, Ery-Est was demonstrated to protect against vertical transmission of" exact="ZIKV" post="in pregnant mice, indicating it may have a good"/>
 <result pre="women. In our study, besides the inhibitory activity against different" exact="ZIKV" post="strains, Ery-Est was also demonstrated to potently inhibit other"/>
 <result pre="was also demonstrated to potently inhibit other mosquito-borne flaviviruses, including" exact="DENV" post="and YFV. This presents an opportunity for clinical applications"/>
 <result pre="for clinical applications to patients, who may suffer co-infections by" exact="ZIKV" post="and DENV, in epidemic areas where the viral vector,"/>
 <result pre="Aedes aegypti, is prevalent. Moreover, it was reported that preexisting" exact="DENV" post="antibodies may aggravate the ZIKV infection through an antibody-dependent"/>
 <result pre="it was reported that preexisting DENV antibodies may aggravate the" exact="ZIKV" post="infection through an antibody-dependent enhancement (ADE) effect [54,55], the"/>
 <result pre="micromolecular inhibitors that target viral binding, endocytosis, and replication against" exact="ZIKV" post="have been discovered, but their suppressing activities are only"/>
 <result pre="inactivator like Z2 that is a synthetic peptide derived from" exact="ZIKV" post="envelope proteins, makes it possible to effectively inhibit ZIKV"/>
 <result pre="from ZIKV envelope proteins, makes it possible to effectively inhibit" exact="ZIKV" post="before viral entry and is, therefore, beneficial to treat"/>
 <result pre="of Ery-Est and other inhibitors with different inhibitory stages against" exact="ZIKV" post="may have synergistic effects of improving protection. In conclusion,"/>
 <result pre="be further repurposed as a novel antiviral drug to treat" exact="ZIKV" post="infection in populations with high risk, particularly pregnant women."/>
 <result pre="available online at https://www.mdpi.com/1999-4915/11/11/1064/s1, Figure S1: Inhibition of Ery-Est against" exact="ZIKV" post="in BHK21 and Vero cells through CCK8 assay. Figure"/>
 <result pre="cells through CCK8 assay. Figure S2: Inhibition of Ery-Est against" exact="ZIKV" post="in multiple rounds of infection; Inhibitory activity of Ery-Est"/>
 <result pre="dose infection of ZIKV. Figure S3: Inhibition of Ery-Est against" exact="ZIKV" post="(V-ZIKV) prepared in Vero cells. LINK Click here for"/>
 <result pre="NigeriaTrans. R Soc. Trop. Med. Hyg.19544813914510.1016/0035-9203(54)90006-113157159 3.MussoD.NillesE.J.Cao-LormeauV.M.Rapid spread of emerging" exact="Zika" post="virus in the Pacific areaClin. Microbiol. Infect.201420O595O59610.1111/1469-0691.1270724909208 4.JouannicJ.M.FriszerS.Leparc-GoffartI.GarelC.Eyrolle-GuignotD.Zika virus"/>
 <result pre="a global public health emergency, declares WHOBMJ2016352i65710.1136/bmj.i65726839247 7.TsetsarkinK.A.MaximovaO.A.LiuG.KenneyH.TeterinaN.BloomM.E.GrabowskiJ.M.MleraL.NagataB.M.MooreI.et al.Routes of" exact="Zika" post="virus dissemination in the testis and epididymis of immunodeficient"/>
 <result pre="MoraesC.G.PettitoM.YepezJ.B.SakuntabhaiA.Simon-LoriereE.ZaidiM.B.ProtM.RuffieC.KimS.S.AllikmetsR.et al.Corrigendum: Optic neuropathy and congenital glaucoma associated with probable" exact="Zika" post="virus infection in Venezuelan patientsJMM Case Rep.20185e00516110.1099/jmmcr.0.00516130323937 9.MalkkiH.CNS infections:"/>
 <result pre="Zika virus infection in Venezuelan patientsJMM Case Rep.20185e00516110.1099/jmmcr.0.00516130323937 9.MalkkiH.CNS infections:" exact="Zika" post="virus infection could trigger Guillain-Barre syndromeNat. Rev. Neurol.20161218710.1038/nrneurol.2016.3026988905 10.CarteauxG.MaquartM.BedetA.ContouD.BrugieresP.FouratiS.Cleret"/>
 <result pre="officials reportBMJ2016352i72010.1136/bmj.i72026848011 13.DengY.Q.ZhangN.N.LiC.F.TianM.HaoJ.N.XieX.P.ShiP.Y.QinC.F.Adenosine Analog NITD008 Is a Potent Inhibitor of" exact="Zika" post="VirusOpen Forum Infect. Dis.20163ofw17510.1093/ofid/ofw17527747251 14.DelvecchioR.HigaL.M.PezzutoP.ValadaoA.L.GarcezP.P.MonteiroF.L.LoiolaE.C.DiasA.A.SilvaF.J.AliotaM.T.et al.Chloroquine, an Endocytosis Blocking"/>
 <result pre="Forum Infect. Dis.20163ofw17510.1093/ofid/ofw17527747251 14.DelvecchioR.HigaL.M.PezzutoP.ValadaoA.L.GarcezP.P.MonteiroF.L.LoiolaE.C.DiasA.A.SilvaF.J.AliotaM.T.et al.Chloroquine, an Endocytosis Blocking Agent, Inhibits" exact="Zika" post="Virus Infection in Different Cell ModelsViruses2016832210.3390/v8120322 15.LiC.DengY.Q.WangS.MaF.AliyariR.HuangX.Y.ZhangN.N.WatanabeM.DongH.L.LiuP.et al.25-Hydroxycholesterol Protects"/>
 <result pre="Infection in Different Cell ModelsViruses2016832210.3390/v8120322 15.LiC.DengY.Q.WangS.MaF.AliyariR.HuangX.Y.ZhangN.N.WatanabeM.DongH.L.LiuP.et al.25-Hydroxycholesterol Protects Host against" exact="Zika" post="Virus Infection and Its Associated Microcephaly in a Mouse"/>
 <result pre="Bioactives Reveals Nanchangmycin as a Broad Spectrum Antiviral Active against" exact="Zika" post="VirusCell Rep.20171880481510.1016/j.celrep.2016.12.06828099856 17.ArabiY.M.DeebA.M.Al-HameedF.MandourahY.AlmekhlafiG.A.SindiA.A.Al-OmariA.ShalhoubS.MadyA.AlraddadiB.et al.Macrolides in critically ill patients with"/>
 <result pre="Aedes aegyptiPLoS Negl. Trop. Dis.20191310.1371/journal.pntd.0007681 20.BosseboeufE.AubryM.NhanT.PinaJ.J.RolainJ.M.RaoultD.MussoD.Azithromycin Inhibits the Replication of" exact="Zika" post="VirusJ. Antivir. Antiretrovir.20181061110.4172/1948-5964.1000173 21.IannettaM.IppolitoG.NicastriE.Azithromycin Shows Anti-Zika Virus Activity in"/>
 <result pre="Proc. Natl. Acad. Sci. USA2016113144081441310.1073/pnas.161802911327911847 23.WuY.H.TsengC.K.LinC.K.WeiC.K.LeeJ.C.YoungK.C.ICR suckling mouse model of" exact="Zika" post="virus infection for disease modeling and drug validationPLoS Negl."/>
 <result pre="24.DengY.Q.ZhaoH.LiX.F.ZhangN.N.LiuZ.Y.JiangT.GuD.Y.ShiL.HeJ.A.QinC.F.et al.Isolation, identification and genomic characterization of the Asian lineage" exact="Zika" post="virus imported to ChinaSci. China Life Sci.20165942843010.1007/s11427-016-5043-426993654 25.LahonA.AryaR.P.KneubehlA.R.VogtM.B.Dailey GarnesN.J.Rico-HesseR.Characterization"/>
 <result pre="imported to ChinaSci. China Life Sci.20165942843010.1007/s11427-016-5043-426993654 25.LahonA.AryaR.P.KneubehlA.R.VogtM.B.Dailey GarnesN.J.Rico-HesseR.Characterization of a" exact="Zika" post="Virus Isolate from ColombiaPLoS Negl. Trop. Dis.201610e000501910.1371/journal.pntd.000501927654889 26.DengY.Q.DaiJ.X.JiG.H.JiangT.WangH.J.YangH.O.TanW.L.LiuR.YuM.QinC.F.et al.A"/>
 <result pre="of E proteinPLoS ONE20116e1605910.1371/journal.pone.001605921264311 27.YuY.DengY.Q.ZouP.WangQ.DaiY.YuF.DuL.QinC.F.JiangS.LuL.et al.A peptide-based viral inactivator inhibits" exact="Zika" post="virus infection in pregnant mice and fetusesNat. Commun.201781567210.1038/ncomms1567228742068 28.XieJ.LiuJ.H.LiuH.LiaoX.Z.ChenY.LinM.G.GuY.Y.LiuT.L.WangD.M.GeH.et"/>
 <result pre="cell line in a synergistic wayBMC Cancer20161689910.1186/s12885-016-2921-x27863471 29.EspanoE.NamJ.H.SongE.J.Lipophilic statins inhibit" exact="Zika" post="virus production in Vero cellsSci. Rep.201991146110.1038/s41598-019-47956-131391514 30.MounceB.C.CesaroT.CarrauL.ValletT.VignuzziM.Curcumin inhibits Zika"/>
 <result pre="inhibit Zika virus production in Vero cellsSci. Rep.201991146110.1038/s41598-019-47956-131391514 30.MounceB.C.CesaroT.CarrauL.ValletT.VignuzziM.Curcumin inhibits" exact="Zika" post="and chikungunya virus infection by inhibiting cell bindingAntivir. Res.201714214815710.1016/j.antiviral.2017.03.01428343845"/>
 <result pre="genome induced by a peptide inhibitorPLoS ONE20127e5099510.1371/journal.pone.005099523226444 36.AliotaM.T.CaineE.A.WalkerE.C.LarkinK.E.CamachoE.OsorioJ.E.Characterization of Lethal" exact="Zika" post="Virus Infection in AG129 MicePLoS Negl. Trop. Dis.201610e000468210.1371/journal.pntd.000468227093158 37.LiS.ArmstrongN.ZhaoH.HouW.LiuJ.ChenC.ZhongC.LiuC.ZhuH.XiaN.et"/>
 <result pre="Nervous SystemViruses2018104910.3390/v10010049 38.ChanJ.F.YipC.C.TsangJ.O.TeeK.M.CaiJ.P.ChikK.K.ZhuZ.JinD.Y.ChanK.H.YuenK.Y.et al.Differential cell line susceptibility to the emerging" exact="Zika" post="virus: Implications for disease pathogenesis, non-vector-borne human transmission and"/>
 <result pre="Anti-ZIKV Activity in Human Breast MilkViruses20191159110.3390/v11070591 40.DaiL.SongJ.LuX.DengY.Q.MusyokiA.M.ChengH.ShiY.QinC.F.QiJ.GaoG.F.et al.Structures of the" exact="Zika" post="Virus Envelope Protein and Its Complex with a Flavivirus"/>
 <result pre="a Flavivirus Broadly Protective AntibodyCell Host Microbe20161969670410.1016/j.chom.2016.04.01327158114 41.ParkJ.G.Avila-PerezG.MadereF.HilimireT.A.NogalesA.AlmazanF.Martinez-SobridoL.Potent Inhibition of" exact="Zika" post="Virus Replication by Aurintricarboxylic AcidFront. Microbiol.20191071810.3389/fmicb.2019.0071831031722 42.RazaS.AbbasG.AzamS.S.Screening pipeline for"/>
 <result pre="Aurintricarboxylic AcidFront. Microbiol.20191071810.3389/fmicb.2019.0071831031722 42.RazaS.AbbasG.AzamS.S.Screening pipeline for Flavivirus based Inhibitors for" exact="Zika" post="Virus NS1IEEE/ACM Trans. Comput. Biol. Bioinform.201910.1109/TCBB.2019.2911081 43.GorshkovK.ShiryaevS.A.FertelS.LinY.W.HuangC.T.PintoA.FarhyC.StronginA.Y.ZhengW.TerskikhA.V.Zika Virus: Origins,"/>
 <result pre="Pregnant Women and InfantsAdv. Neonatal Care20181835035910.1097/ANC.000000000000055730239403 50.MotaV.M.R.CavalcantiL.P.G.DelfinoA.D.S.LopesT.PessoaA.L.S.RibeiroE.M.Abortion in Cases of" exact="Zika" post="Virus Congenital InfectionRev. Bras. Ginecol. Obstet.20184041742410.1055/s-0038-164821929959761 51.CuiL.ZouP.ChenE.YaoH.ZhengH.WangQ.ZhuJ.N.JiangS.LuL.ZhangJ.Visual and Motor"/>
 <result pre="Obstet.20184041742410.1055/s-0038-164821929959761 51.CuiL.ZouP.ChenE.YaoH.ZhengH.WangQ.ZhuJ.N.JiangS.LuL.ZhangJ.Visual and Motor Deficits in Grown-up Mice with Congenital" exact="Zika" post="Virus InfectionEBioMedicine20172019320110.1016/j.ebiom.2017.04.02928583742 52.SakkasH.BozidisP.GiannakopoulosX.SofikitisN.PapadopoulouC.An update on sexual transmission of Zika"/>
 <result pre="Congenital Zika Virus InfectionEBioMedicine20172019320110.1016/j.ebiom.2017.04.02928583742 52.SakkasH.BozidisP.GiannakopoulosX.SofikitisN.PapadopoulouC.An update on sexual transmission of" exact="Zika" post="virusPathogens201876610.3390/pathogens7030066 53.DuggalN.K.RitterJ.M.PestoriusS.E.ZakiS.R.DavisB.S.ChangG.J.BowenR.A.BraultA.C.Frequent Zika Virus Sexual Transmission and Prolonged Viral"/>
 <result pre="InfectionEBioMedicine20172019320110.1016/j.ebiom.2017.04.02928583742 52.SakkasH.BozidisP.GiannakopoulosX.SofikitisN.PapadopoulouC.An update on sexual transmission of Zika virusPathogens201876610.3390/pathogens7030066 53.DuggalN.K.RitterJ.M.PestoriusS.E.ZakiS.R.DavisB.S.ChangG.J.BowenR.A.BraultA.C.Frequent" exact="Zika" post="Virus Sexual Transmission and Prolonged Viral RNA Shedding in"/>
 <result pre="Immunodeficient Mouse ModelCell Rep.2017181751176010.1016/j.celrep.2017.01.05628199846 54.GunawardanaS.A.ShawR.H.Cross-reactive dengue virus-derived monoclonal antibodies to" exact="Zika" post="virus envelope protein: Panacea or Pandora’s box?BMC Infect. Dis.20181864110.1186/s12879-018-3572-030526531"/>
 <result pre="or Pandora’s box?BMC Infect. Dis.20181864110.1186/s12879-018-3572-030526531 55.LiM.ZhaoL.ZhangC.WangX.HongW.SunJ.LiuR.WangJ.ZhangF.JinX.et al.Dengue immune sera enhance" exact="Zika" post="virus infection in human peripheral blood monocytes through Fc"/>
 <result pre="of dengue virusCurr. Opin. Virol.2019361810.1016/j.coviro.2019.02.00230844538 58.SapparapuG.FernandezE.KoseN.BinC.FoxJ.M.BombardiR.G.FremontD.H.DoranzB.J.DiamondM.S.CroweJ.E.et al.Neutralizing human antibodies prevent" exact="Zika" post="virus replication and fetal disease in miceNature201654044344710.1038/nature2056427819683 Figure 1"/>
 <result pre="erythromycin estolate (Ery-Est) and Ery and their inhibitory activity against" exact="Zika" post="virus (ZIKV) in different cell types. (A) The molecular"/>
 <result pre="Ery. (B) BHK21 cells (2 × 106) were infected by" exact="ZIKV" post="strain SZ01 that were treated with serial concentrations of"/>
 <result pre="(D) U-251 MG cells (2 × 105) were infected by" exact="ZIKV" post="treated with different concentrations of Ery-Est and Ery. The"/>
 <result pre="BHK21 and Vero cells (2 × 105) were infected with" exact="ZIKV" post="strain SZ01 and treated by Ery-Est and Ery, then"/>
 <result pre="strain SZ01 and treated by Ery-Est and Ery, then the" exact="ZIKV" post="infection was evaluated by immunofluorescence staining after 4 days."/>
 <result pre="ZIKV infection was evaluated by immunofluorescence staining after 4 days." exact="ZIKV" post="E protein were stained by mAb 4G2 (green); nuclei"/>
 <result pre="its cytotoxicity. BHK21 cells (2 × 106) were infected by" exact="ZIKV" post="strains (A) FLR, (B) MR766, (C) DENV II, and"/>
 <result pre="were infected by ZIKV strains (A) FLR, (B) MR766, (C)" exact="DENV" post="II, and (D) YFV 17D with the treatment of"/>
 <result pre="strains (A) FLR, (B) MR766, (C) DENV II, and (D)" exact="YFV" post="17D with the treatment of serial concentrations of Ery-Est"/>
 <result pre="0.001; **** p &amp;lt; 0.0001. Figure 3 Early stages of" exact="ZIKV" post="infection were inhibited by Ery-Est. (A) BHK21 cells (2"/>
 <result pre="Ery-Est. (A) BHK21 cells (2 × 106) were infected with" exact="ZIKV" post="SZ01 and Ery-Est was added at different time points"/>
 <result pre="viral lifecycle. In the entry experiment, cells were infected with" exact="ZIKV" post="SZ01 in the presence of Ery-Est, Azi, Ery, or"/>
 <result pre="four experiments were evaluated by plaque assay. (C) ZIKV, (D)" exact="DENV" post="II, and (E) YFV 17D were respectively treated by"/>
 <result pre="by plaque assay. (C) ZIKV, (D) DENV II, and (E)" exact="YFV" post="17D were respectively treated by Ery-Est at 37 °C"/>
 <result pre="measured for their infectivity. Degradation of released genomic RNA of" exact="ZIKV" post="treated by (F) Ery-Est or (G) Ery in an"/>
 <result pre="protein was detected. The separation of E protein and of" exact="ZIKV" post="treated by Ery-Est, Ery, 1% DMSO, and Triton X-100"/>
 <result pre="p &amp;lt; 0.0001. Figure 4 Protective activity of Ery-Est against" exact="ZIKV" post="infection in lethal mouse models. Three groups of A129"/>
 <result pre="50 mg/kg respectively (n = 8). Mice administrated with heat-inactivated" exact="ZIKV" post="(iZIKV) or only administrated with Ery-Est and Ery were"/>
 <result pre="Figure 5 Protective activity of Ery-Est against vertical transmission of" exact="ZIKV" post="in pregnant C57BL/6 mice. C57BL/6 pregnant mice were infected"/>
</results>
